# Riluzole Oral Suspension: FDA shortage status

> FDA source status only. Nationwide status is not local pharmacy inventory. This page does not provide medical, treatment, substitution, or dosing advice.

- Derived status: current
- Source statuses: Current
- FDA package records: 4
- Latest FDA row update: 08/17/2026
- Retrieved: 2026-08-22T15:54:11+00:00

## FDA package and manufacturer records

- EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) — Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1) — FDA availability: Available — updated: 08/17/2026
- EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) — Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1) — FDA availability: Available — updated: 08/17/2026
- EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) — Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1) — FDA availability: Available — updated: 08/17/2026
- EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) — Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1) — FDA availability: Unavailable — updated: 08/17/2026

## Sources and formats

- [FDA openFDA source](https://api.fda.gov/drug/shortages.json)
- [Canonical HTML](https://citefacts.com/shortages/riluzole-oral-suspension)
- [JSON record](https://citefacts.com/shortages/riluzole-oral-suspension.json)